Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study

Haemophilia. 2015 Sep;21(5):e369-74. doi: 10.1111/hae.12740. Epub 2015 Jul 14.

Abstract

Introduction: Central venous access devices (CVADs) are frequently required as stable long-lasting venous access in children with haemophilia, especially those requiring immune tolerance induction (ITI) for inhibitors. CVAD infection is one of the most frequently reported catheter-related complications in this patient population.

Aim: Detailed review of CVAD complications from the International ITI (I-ITI) study and analysis of potential risk factors for such complications.

Methods: Retrospective analysis of prospectively obtained data from the I-ITI study primarily focused on CVAD-related complications.

Results: A total of 115 children were recruited and 183 CVADs were placed in 99 subjects resulting in 121,206 CVAD-days observed on-study. A total of 124 CVAD infections were reported in 41 of 99 (41%) subjects with an overall infection rate of 0.94 per 1000 CVAD-days (interquartile ranges 0-1.7). A similar number of infections were observed in the two treatment arms (median: 2 and 3 in high dose and low dose respectively). Infections occurred more frequently in the presence of external catheters than with fully implanted catheters (P = 0.026). Infected patients were significantly younger at the time of CVAD insertion (median age: 22 vs. 25 months, P = 0.020). Patients with Gram-positive infections were also significantly younger than those with Gram-negative infections (median age: 17 vs. 25 months, P < 0.0001).

Conclusion: CVAD infection was the most common complication observed in children with severe haemophilia and inhibitors in the frame of the I-ITI study. Younger age at CVAD insertion and external CVAD were associated with higher risk for infection. ITI outcome was unaffected by CVAD infections.

Keywords: central venous access; complications; immune tolerance; inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies / immunology*
  • Catheterization, Central Venous* / adverse effects
  • Child
  • Child, Preschool
  • Hemophilia A / immunology*
  • Humans
  • Immune Tolerance*
  • Infant
  • Infant, Newborn
  • Internationality*
  • Prosthesis-Related Infections / etiology
  • Risk Factors
  • Time Factors

Substances

  • Antibodies